BioLife Solutions

BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.

Earnings data Q1 2024

BioLife Solutions reports Q1 revenue growth, explores strategic alternatives

BioLife Solutions reported solid revenue growth and improved gross margin, but faces challenges with certain business segments. The company's strong position in the cell and gene therapy industry presents growth opportunities, while strategic review may lead to new avenues for value creation.

BioLife Solutions reports Q2 revenue decline, focuses on higher-margin streams

BioLife Solutions reported a decrease in Q2 2023 revenue but is focused on higher-margin streams and anticipates a recovery in 2024. The company is divesting certain assets and planning to build a new production facility to meet anticipated demand. It faces challenges in the sequential performance of the Cell Processing platform and questions about industry destocking.

BioLife Solutions reports Q3 revenue decline, eyes growth in gene therapy

BioLife Solutions faced revenue declines and increased operating expenses in Q3 2023, leading to negative adjusted EBITDA. However, the company is optimistic about weathering the challenges and has taken steps to streamline operations and improve efficiency. Despite the current challenges, BioLife sees opportunities in the cell and gene therapy market and aims to adapt and grow in this space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOTHELL, Wash. , April 18, 2024 /PRNewswire/ --  BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced that it has completed the divestiture of its wholly owned subsidiary Global Cooling, Inc. ("GCI" or "Stirling").

BioLife Solutions Announces the Divestiture of its Stirling Freezer Business

BOTHELL, Wash. , March 4, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced that Roderick de Greef, Chief Executive Officer, and Troy Wichterman, Chief Financial Officer, will present and meet with current and prospective investors at the following March Investor Conferences.

BioLife Solutions to Present at TD Cowen and Key Bank Investor Conferences

BioLife Solutions, Inc. (BLFS) Q4 2024 Earnings Call Transcript

Fourth quarter Cell Processing revenue up 11% sequentially to $14.8 million, and positive adjusted EBITDA of $700,000 Expects 2024 revenue of $95.5 - $100.0 million excluding freezer business and positive adjusted EBITDA Conference call begins at 4:30 p.m. Eastern time today  BOTHELL, Wash.

BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results

BOTHELL, Wash. , Feb. 20, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's fourth quarter and full year 2023 financial results will be released after market close on Thursday, February 29, 2024.

BioLife Solutions to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update on February 29, 2024

Fourth quarter Cell Processing revenue increased 11% sequentially to $14.8 million BOTHELL, Wash. , Jan. 8, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced 2023 fourth quarter and full year preliminary unaudited revenue.

BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue

BioLife Solutions, Inc. is trading near 52-week lows as its growth story has floundered and profitability remains uncertain. The company offers bioproduction tools and services for the cell and gene therapy industry, with recurring revenue streams making up about 65% of its revenue. The cell and gene therapy market is expected to continue growing, but BioLife's recent financial performance and management changes have caused concern.

BioLife Solutions: A Complicated Tale

BioLife Solutions, Inc. (NASDAQ:BLFS ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Troy Wichterman - CFO Rod de Greef - Chairman and CEO Conference Call Participants Jacob Johnson - Stephen Matt Hewitt - Craig-Hallum Paul Knight - KeyBanc Steven Mah - TD Cowen Thomas Flaten - Lake Street Michael Okunewitch - Maxim Group Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2023 Shareholder and Analyst Conference Call.

BioLife Solutions, Inc. (BLFS) Q3 2023 Earnings Call Transcript

Conference call begins at 4:30 p.m. Eastern time today  BOTHELL, Wash.

BioLife Solutions Reports Third Quarter 2023 Financial Results

BOTHELL, Wash. , Nov. 2, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter financial results will be released after market close on Thursday, November 9, 2023.

BioLife Solutions to Provide Third Quarter 2023 Financial Results and Business Update on November 9, 2023

Roderick de Greef appointed Chairman and Chief Executive Officer bringing 20+ years of prior BioLife experience Garrie Richardson appointed Chief Revenue Officer Preliminary Q3 revenue of $33.3 million and expect 2023 revenue at the low end of the previously announced guidance range  BOTHELL, Wash. , Oct. 19, 2023 /PRNewswire/ --  BioLife Solutions , Inc. (NASDAQ: BLFS ), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced Roderick de Greef has been appointed as Chairman of the Board of Directors and Chief Executive Officer replacing Michael Rice who is retiring after a seventeen year tenure, effective immediately.

BioLife Solutions Announces Leadership Transitions & Preliminary Third Quarter Revenue with Updated Outlook for 2023

Bowman Consulting Group

Fuel Tech

BLFS, BWMN and FTEK have been added to the Zacks Rank #5 (Strong Sell) List on October 9, 2023.

New Strong Sell Stocks for October 9th

AFC Gamma

Alico

BLFS, ALCO and AFCG have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2023.

New Strong Sell Stocks for September 13th

BioLife is facing setbacks due to a difficult funding environment, inventory corrections, and a decline in COVID-related revenues. The company's acquisitions have negatively impacted margins and cash flow. Management plans to divest the freezer business, which is expected to improve financials and the balance sheet and will provide an impetus for the stock.

BioLife Hit By An Inventory Correction

Allakos Inc

Cano Health

Kezar Life Sciences Inc

Alaunos Therapeutics

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Could Blast Off This Month - Allakos (NASDAQ:ALLK), BioLife Solns (NASDAQ:BLFS)

BioLife Solutions focuses on cell- and gene-therapy preservation tools, used primarily by the biotech industry. The company did trim its losses, year over year, in the quarter.

Why Shares of BioLife Solutions Plummeted This Week

BioLife Solutions said it is divesting itself of some assets to focus on its higher-margin business. The company saw declining revenue but narrowed its losses dramatically.

Why Shares of BioLife Solutions Are Slumping on Wednesday

BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $1.71 per share a year ago.

BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Misses Revenue Estimates

Committed to Divesting Stirling Ultracold and Custom Biogenic Systems by End of 2023 Conference call begins at 4:30 p.m. Eastern time today  BOTHELL, Wash.

BioLife Solutions Reports Second Quarter 2023 Financial Results, Updates Full Year 2023 Guidance and Provides Pro Forma First Half 2023 Financial Profile Excluding Freezer Business

BOTHELL, Wash. , July 27, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's second quarter financial results will be released after market close on Tuesday, August 8, 2023.

BioLife Solutions to Provide Second Quarter 2023 Financial Results and Business Update on August 8, 2023

BOTHELL, Wash. , June 14, 2023 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS ), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced that all of its SciSafe-branded biostorage facilities in the USA have been accredited by the College of American Pathologists (CAP).

BioLife Solutions Receives College of American Pathologists CAP-BAP Accreditation for All SciSafe® U.S. Biostorage Facilities

Large-Capacity Tabletop Freezer Expands Line of Controlled-Rate Freezers for Cell and Gene Therapies; Now Available for Order BOTHELL, Wash. , June 6, 2023 /PRNewswire/ -- BioLife Solutions, Inc.  (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced the launch of a new, large-capacity controlled-rate freezer (CRF) to expand its CRF product line, which now stands at three different form factors.

BioLife Solutions Launches the IntelliRate™ i67C Liquid Nitrogen (LN2) Controlled-Rate Freezer

BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Troy Wichterman - CFO Michael Rice - Chairman & CEO Conference Call Participants Jacob Johnson - Stephens Inc. Thomas Flaten - Lake Street Capital Markets Chad Wiatrowski - TD Cowen Carl Byrnes - Northland Capital Markets Yuan Zhi - B. Riley Securities Paul Knight - KeyBanc Capital Markets Operator Hello.

BioLife Solutions, Inc. (BLFS) Q1 2023 Earnings Call Transcript

BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.17 per share a year ago.

BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Misses Revenue Estimates

Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28% Q1 2023 Adjusted gross margin improvement; 37% compared to 32% in Q4 2022 Decision to Explore Strategic Alternatives for Ultra-Low Temperature and Cryogenic Freezer Product Lines Conference call begins at 4:30 p.m. Eastern time today  BOTHELL, Wash.

News for BioLife Solutions Stock (BLFS)